Oxford, UK – 13 September 2010. OGT, provider of innovative genetics and biomarker solutions to advance molecular medicine, today announced that it has been certified compliant with ISO/IEC 27001:2005, an international information security management standard. Extending to all data generation and security procedures, including OGT’s CytoSure® and Genefficiency™ services, biomarker discovery solutions, and the development of CytoSure Interpret Software, this certification acknowledges that data confidentiality, availability and integrity is carefully managed and controlled.
Building on the ISO 9001:2008 registration earlier this year, OGT’s new ISO/IEC 27001:2005 certification provides clear evidence of robust information security to meet all customer needs. Dr Mike Evans, OGT’s CEO, commented: “Being one of only 448 companies within the UK to be compliant with ISO/IEC 27001:2005 demonstrates our ongoing commitment to information security and confidentiality. It also emphasises the dedication and reliability of our team to provide high-quality products and services, while protecting the integrity and confidentiality of all information and data.”
The ISO/IEC 27001:2005 certification was awarded following an assessment by the British Standards Institution (BSI).
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
New content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read